REQUIP

LOE Approaching

ropinirole hydrochloride

NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Clinical Trials (5)

NCT01536574Phase 3Completed

Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Started Sep 2010
295 enrolled
Parkinson Disease
NCT00485069Phase 4Completed

REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study

Started Jun 2007
123 enrolled
Parkinson DiseaseParkinson's Disease
NCT00334048Phase 4Completed

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

Started Jun 2006
9 enrolled
Sexual Dysfunction
NCT01327339N/ACompleted

REQUIP RLS Post Marketing Surveillance

Started Apr 2006
755 enrolled
Restless Legs Syndrome
NCT00260793Phase 3Unknown

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Started Nov 2005
20 enrolled
Parkinson's Disease